Preclinical data reinforce therapeutic potential of ATX-559, a first-in-class oral DHX9 inhibitor, in cancers characterized by genomic instability and replication stress Novel KIF18A inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback